These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16314737)

  • 41. Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma.
    Stables GI; Doherty VR; MacKie RM
    Br J Dermatol; 1992 Nov; 127(5):505-8. PubMed ID: 1281672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between clinical features and course of systemic sclerosis and serum interleukin-8, vascular endothelial growth factor, basic fibroblast growth factor, and interferon alpha.
    Kosałka-Węgiel J; Lichołai S; Dziedzina S; Milewski M; Kuszmiersz P; Korona A; Korkosz M; Gąsior J; Matyja-Bednarczyk A; Kwiatkowska H; Siwiec-Koźlik A; Sydor W; Wilańska J; Zaręba L; Pociej-Marciak W; Dropiński J; Sanak M; Musiał J; Bazan-Socha S
    Adv Clin Exp Med; 2024 Apr; 33(4):369-377. PubMed ID: 37540156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma.
    Pectasides D; Alevizakos N; Bafaloukos D; Tzonou A; Asimakopoulos G; Varthalitis I; Dimitriadis M; Athanassiou A
    Am J Clin Oncol; 1994 Feb; 17(1):55-9. PubMed ID: 8311008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
    Inanç M; Er O; Karaca H; Berk V; Ozkan M; Saraymen R; Elmalı F
    Med Oncol; 2012 Dec; 29(5):3119-24. PubMed ID: 22580817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F; Candeloro G; Necozione S; Fumagalli L; Bratta M; Rea S
    Anticancer Drugs; 2008 Feb; 19(2):201-7. PubMed ID: 18176117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.
    Triozzi PL; Achberger S; Aldrich W; Singh AD; Grane R; Borden EC
    J Transl Med; 2012 Dec; 10():241. PubMed ID: 23217102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
    Keilholz U; Conradt C; Legha SS; Khayat D; Scheibenbogen C; Thatcher N; Goey SH; Gore M; Dorval T; Hancock B; Punt CJ; Dummer R; Avril MF; Bröcker EB; Benhammouda A; Eggermont AM; Pritsch M
    J Clin Oncol; 1998 Sep; 16(9):2921-9. PubMed ID: 9738559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
    Richards JM; Mehta N; Ramming K; Skosey P
    J Clin Oncol; 1992 Aug; 10(8):1338-43. PubMed ID: 1634924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
    Di Lauro V; Scalone S; La Mura N; Zanetti M; Nigri P; Freschi A; Veronesi A
    Melanoma Res; 2005 Jun; 15(3):209-12. PubMed ID: 15917704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
    Grignol VP; Olencki T; Relekar K; Taylor C; Kibler A; Kefauver C; Wei L; Walker MJ; Chen HX; Kendra K; Carson WE
    J Immunother; 2011; 34(6):509-15. PubMed ID: 21654521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Changes of serum angiogenesis in patients with chronic mountain sickness].
    Yan JH; Li ZQ; Ji LH; Chai KX; Ge RL
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2009 Nov; 25(4):457-60. PubMed ID: 21158030
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
    Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
    Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS
    J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
    Keilholz U; Martus P; Punt CJ; Kruit W; Mooser G; Schadendorf D; Liénard D; Dummer R; Koller J; Voit C; Eggermont AM
    Eur J Cancer; 2002 Jul; 38(11):1501-11. PubMed ID: 12110497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
    Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
    Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.